GE HealthCare to buy SOFIE Biosciences for $945M in radiopharma push
What's the deal? GE HealthCareDealroom has a profile for this one. Try Dealroom → has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. It is buying the company from private equity firm Trilantic North AmericaDealroom has a profile for this one. Try Dealroom →, with the transaction expected to close in the first half of 2027, subject to regulatory approvals.
What's the endgame? The deal gives GE HealthCare a foothold in the time-critical "final mile" of US PET radiopharmaceutical supply. SOFIE brings a network of 15 contract manufacturing sites, 21 cyclotrons, and a theranostics-focused development and manufacturing operation.
Why now? PET radiopharmaceuticals have a short shelf life — F18-labelled products carry a 110-minute half-life — making local manufacturing essential to reaching patients in time. The industry pipeline is expanding fast, with roughly 20 PET radiotracers and over 30 radiotherapeutics in development.
SOFIE already manufactures GE HealthCare's Flyrcado product and holds a Phase III asset, FAPI-74, for which GE HealthCare owns rights outside the US. Once integrated into GE HealthCare's PDx segment, SOFIE is expected to grow in the low double digits, according to the company.
What changes for customers? After closing, SOFIE will keep operating as an independent manufacturing partner, continuing to supply its existing portfolio, including products from other radiopharmaceutical providers.
"We will leverage our scale and expertise in radiopharmaceutical manufacturing across the U.S., Europe and Japan to further invest in and grow SOFIE Biosciences," said Kevin O'Neill, president and chief executive officer of the PDx segment.
The signal: The acquisition reflects a broader push by imaging and diagnostics firms to control the full theranostics pathway — from cyclotrons to imaging technology to radiotherapeutics — as targeted precision medicine gains traction. For GE HealthCare, owning manufacturing capacity closer to patients turns supply reliability into a competitive edge in a market expanding alongside its drug pipeline.
Read more: businesswire.com
Image credit: National Institutes of Health (NIH)
